4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Dystonia by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 43 ongoing clinical trials involving Dystonia
Of the 43 trials,21 trials are in Phase II
Furthermore, 11 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Dystonia by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Dystonia, a Central Nervous System disorder. The highest number of ongoing clinical trials involving Dystonia is in North America. Asia-Pacific and Europe are among some of the other prominent regions involved in Dystonia-related drug trials.

AEON Biopharma Inc.: The leading ongoing Dystonia-related clinical trials sponsor

AEON Biopharma Inc, the United States of America-based pharmaceutical company, is the top sponsor for Dystonia-related ongoing clinical trials.

Chulalongkorn University, Addex Therapeutics Ltd, Massachusetts Eye and Ear Infirmary, Mayo Clinic, and University of Texas Southwestern Medical Center are a few other notable sponsors involving Dystonia.

A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Dystonia

Onabotulinumtoxin A (Botox), Abobotulinumtoxin A (Dysport, Botulinum Toxin Type A, Azzalure), and Rimabotulinumtoxin B (Botulinum Toxin Type B/ NeuroBloc/ Myobloc/ Nerbloc) are among the key marketed drugs involving Dystonia.

Onabotulinumtoxin A (Botox), a Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25) Inhibitor, is indicated for cervical dystonia, chronic migraine, axillary hyperhidrosis, blepharospasm, strabismus, blepharospasm, muscle spasm, overactive bladder, and urinary incontinence. The drug is marketed globally including in the US, the UK, France, Germany, China, and Japan by several prominent pharma giants including Allergan Sales LLC, GlaxoSmithKline (China) Ltd, GlaxoSmithKline KK, and Allergan Ltd. Onabotulinumtoxin was first approved in 1991 and formulated as injectable powder solution for an intramuscular, subcutaneous and intradermal route of administration.

Abobotulinumtoxin A (Dysport, Botulinum Toxin Type A, Azzalure), a Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25) Inhibitor, is indicated for the treatment of cervical dystonia in adults for reducing the severity of abnormal head position and neck pain in both toxin-naive and previously treated patients. The drug is marketed globally including in the US, the UK, Australia, France, and Germany by several prominent pharma giants including Ipsen Biopharmaceuticals Inc. Abobotulinumtoxin was first approved in 1990 and formulated as a lyophilized powder for solution, solution for an intramuscular and subcutaneous route of administration.